TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11061574
Drug: Rifampin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin (600 mg per day for 9 days)
Study: 3709018
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol (180 mcg, 2 puffs) followed by hourly albuterol aerosol for 5 hours (10 puffs = 900 mcg)
Study: 20442540
Drug: Aprotinin 20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin 20,000 KIU/kg after induction, 20,000 KIU/kg added to pump prime, 20,000 KIU/kg/hour infusion for three hours
Study: 15876900
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg twice daily)
Study: 12600228
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 or 600mg once daily
Study: 31983019
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy-Enhanced (CBT-E)
Study: 29630438
Drug: RTS,S/AS01 malaria
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 malaria vaccine co-administered with PHiD-CV and HRV
Study: 29630438
Drug: RTS,S/AS01 co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 co-administered with PHiD-CV
Study: 29630438
Drug: RTS,S/AS01 co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 co-administered with HRV
Study: 29630438
Drug: RTS,S/AS01 co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 co-administered with aP antigens
Study: 29630438
Drug: PHiD-CV co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV co-administered with RTS,S/AS01
Study: 29630438
Drug: RTS,S/AS01 co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 co-administered with pediatric vaccines
Study: 29630438
Drug: RTS,S/AS01 and
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01 and co-administered PHiD-CV, pertussis antigens and HRV
Study: 29630438
Drug: HBV (Engerix
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBV (Engerix B) vaccine
Study: 25502179
Drug: CERA administered
Normalized name: CERA
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CERA administered every two weeks (Q2W)
Study: 23301484
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 50 mg dolantin injection followed by oocyte retrieval after 30 min
Study: 20350923
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (group D)
Study: 11190415
Drug: Fluconazole for
Normalized name: Fluconazole for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole for antifungal prophylaxis in patients with prolonged neutropenia
Study: 11190415
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B at a daily dose of 0.6 to 1 mg/kg
Study: 11190415
Drug: Lipid formulations
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid formulations of amphotericin B
Study: 11190415
Drug: New antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New antifungal agents (new azoles)
Study: 318795
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 20 mg
Study: 3881006
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of nifedipine and isosorbide dinitrate
Study: 31637821
Drug: Intervention: Six-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Six-monthly repeat home-based HIV counselling and testing (RHBCT) and referral of PLHIV to local HIV clinics, ART initiated regardless of CD4 count.
Study: 22305197
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral thiamine hydrochloride
Study: 22305197
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral thiamine hydrochloride
Study: 22305197
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg oral thiamine hydrochloride
Study: 10999733
Drug: Octreotide 200
Normalized name: octreotide 200 mcg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 200 microg three times daily
Study: 10999733
Drug: Octreotide 500
Normalized name: 1 ML octreotide 500 MCG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide 500 microg three times daily
Study: 3981952
Drug: Control (common
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (common antihypertensive medications)
Study: 30743107
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (control mares)
Study: 11075769
Drug: Conventional immunosuppression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppression with ATG plus cyclosporin (40 mg/kg daily for 4 days)
Study: 26764356
Drug: High-dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide
Study: 8883753
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 intracervical gel (0.5 mg)
Study: 8883753
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 intravaginal pessary (3 mg)
Study: 9272427
Drug: Ipriflavone 600
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 600 mg/day
Study: 1422319
Drug: Ipriflavone 1200
Normalized name: IPRIFLAVONE
DrugBank: Ipriflavone (DB13618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 1200 mg/day
Study: 1422319
Drug: Ipriflavone 1200/600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone 1200/600 mg/day sequence
Study: 29411360
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive rehabilitation (CR) therapy consisting of eight 2-hour sessions over a 4-week period.
Study: 29411360
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive rehabilitation (CR) therapy
Study: 20163570
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation with transdermal nicotine patch
Study: 19552488
Drug: Blonanserin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin 2.5 mg
Study: 19552488
Drug: Blonanserin 5
Normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Blonanserin 5 mg
Study: 29885904
Drug: Haloperidol 10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10 mg
Study: 16314787
Drug: SRL-CsA-ST (triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL-CsA-ST (triple therapy)
Study: 16314787
Drug: SRL-ST (sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRL-ST (sirolimus and steroids only)
Study: 12225330
Drug: Interferon alone
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alone (monotherapy)
Study: 24903787
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) preventive therapy
Study: 20338901
Drug: PQA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQA plus Nicotine Replacement Therapy (NRT) sampling
Study: 18356837
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day sibutramine for 5 days
Study: 12609786
Drug: Permethrin 5%
Normalized name: PERMETHRIN 5% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 5% cream (P)
Study: 1780723
Drug: Saline injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline injected into the vicinity of the infraorbital foramina (1-1.5 ml)
Study: 31402389
Drug: In-reach rehabilitation
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-reach rehabilitation in addition to usual ward therapy (n=29)
Study: 31402389
Drug: Usual ward
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual ward therapy (n=33)
Study: 30242334
Drug: Oral Valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Valproic Acid
Study: 25572630
Drug: Modified-release calcifediol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified-release calcifediol (30, 60, or 90 µg daily for six weeks)
Study: 19910359
Drug: TENS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS with narcotic analgesics
Study: 19910359
Drug: TENS as
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS as an adjunct to other medications
Study: 19910359
Drug: TENS as
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS as sole pain-control treatment
Study: 9365969
Drug: 30 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg.kg‐1 propacetamol (15 mg.kg‐1 acetaminophen)
Study: 1411329
Drug: Standardized maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized maintenance antipsychotic medication for at least 1 year
Study: 3893694
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered orally (30 mg/m2)
Study: 3893694
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) administered intramuscularly (30 mg/m2)
Study: 29341850
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (monthly self-management education and quarterly medication management facilitation)
Study: 27502820
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure for five days along with standard medications
Study: 27502820
Drug: Standard medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medications only
Study: 24588854
Drug: Subcutaneous human
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous human choriogonadotropin alfa followed by intravenous erythropoietin (4000-20,000 IU/dose)
Study: 22404250
Drug: Standard technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard technique (successive injections of chromated glycerin mixed with one‐third lidocaine‐epinephrine 1%)
Study: 19646775
Drug: LOH, K-ras
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOH, K-ras mutations, and high levels of free plasma DNA (>5ng/ml plasma)
Study: 9658750
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy after EMR for depressed type lesions
Study: 9658750
Drug: Additional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional laser therapy for recurring lesions
Study: 10954007
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg daily)
Study: 2475589
Drug: Supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care and mild cytoreductive chemotherapy (arm B) for palliation of leukemia-associated complications.
Study: 4990
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of ketamine
Study: 25560342
Drug: Furazolidone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone (100 mg PO bid), amoxicillin, and omeprazole
Study: 23794338
Drug: Clarithromycin, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, amoxicillin, and omeprazole
Study: 19997942
Drug: Mosapride citrate
Normalized name: mosapride citrate
DrugBank: Mosapride (DB11675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride citrate (15 mg/day) + Omeprazole (20 mg/day) for 12 weeks
Study: 18418294
Drug: Terameprocol (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terameprocol (90 mg, 2% w/w ointment) administered intravaginally for 7 consecutive days
Study: 16046202
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg preparation
Study: 16046202
Drug: Lamivudine 150
Normalized name: lamivudine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 150 mg preparation
Study: 7484039
Drug: alfentanil 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 0.03 mg.kg‐1
Study: 7788827
Drug: alfentanil 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 0.015 mg.kg‐1 + esmolol 1 mg.kg‐1
Study: 2146812
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin preparation
Study: 2146812
Drug: Placebo preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo preparation consisting of human serum albumin
Study: 26595362
Drug: 0.5-mg conbercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5-mg conbercept
Study: 26595362
Drug: 2.0-mg conbercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0-mg conbercept
Study: 17496674
Drug: Neuromonics Tinnitus
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromonics Tinnitus Treatment (both variations)
Study: 12140623
Drug: Alcohol (1.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (1.05 mg/kg)
Study: 9623685
Drug: SR 27417A
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR 27417A (20 mg)
Study: 8124603
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs or novel drug combinations, new therapeutic modalities, or technological improvements of old modalities
Study: 8124603
Drug: New therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: New therapies that represent modest, incremental advances over existing treatment
Study: 23454694
Drug: Intravenous glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycerol
Study: 56650
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose
Study: 21350204
Drug: Preadmission warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preadmission warfarin use
Study: 19266830
Drug: Midazolam 35
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 35 microg/kg administered intravenously 30 minutes before conclusion of surgery (Group MI)
Study: 17920548
Drug: Blocking monoclonal
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking monoclonal antibodies
Study: 8861661
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice and erythromycin (CYP3A inhibitors)
Study: 1293307
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily for 2 weeks, then increased to 10 mg daily for 4 weeks if DBP was not < 90 mmHg or decreased by > 10 mmHg from baseline.
Study: 6538006
Drug: gamma-vinyl GABA
Normalized name: gamma-Vinyl GABA
DrugBank: Vigabatrin (DB01080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gamma-vinyl GABA (1 g and 2 g daily for 2 weeks each)
Study: 6538006
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (2 weeks)
Study: 27174596
Drug: Fulvestrant plus
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant plus a pan‐PI3K inhibitor
Study: 23294513
Drug: Individual stress-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual stress-management intervention (low-intensity followed by more intensive treatment if needed)
Study: 26930055
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment as usual)
Study: 12811359
Drug: Pregabalin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (various doses: 0, 50, 150, 300, and 600 mg)
Study: 20466589
Drug: Pregabalin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (various doses)
Study: 30448936
Drug: Moderate-intensity aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity aerobic exercise (14 kcal kg-1 body weight weekly)
Study: 30448936
Drug: Moderate-intensity aerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity aerobic exercise (8 kcal kg-1 body weight weekly)
Study: 21939613
Drug: Aripiprazole 5
Normalized name: aripiprazole 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 5 mg/d
Study: 16688841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (600±100 kcal non-protein plus or not plus 62±16 g crystalline amino acids postoperatively)
Study: 11770696
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.25 mg, 0.5 mg, or 1.0 mg once daily for 12 weeks
Study: 30321909
Drug: Galcanezumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab (4 doses)
Study: 29904126
Drug: Intramuscular testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular testosterone undecanoate (n=49)
Study: 16490804
Drug: 1 tablet
Normalized name: Ovral-21 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet of erlotinib 150 mg
Study: 16490804
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intravenous infusion of erlotinib
Study: 11073286
Drug: Closerin capsules
Normalized name: Cloverine
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closerin capsules (250 mg)
Study: 11073286
Drug: Dura seromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dura seromycin capsules (250 mg)
Study: 9196315
Drug: Heparin coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin coated cardiopulmonary bypass (n = 56)
Study: 12477672
Drug: PCA containing
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA containing 20 mg tramadol + 1 mg metoclopramide per millilitre (Group T+M)
Study: 12477672
Drug: PCA containing
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA containing 20 mg tramadol (Group T)
Study: 26466681
Drug: Education messages
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education messages for schistosomiasis prevention + pre-treatment snack (2013)
Study: 26466681
Drug: Education messages
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education messages for schistosomiasis prevention + pre-treatment snack (2014)
Study: 20026777
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus a glycoprotein IIb/IIIa inhibitor
Study: 11265775
Drug: MUC1‐mannan fusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: MUC1‐mannan fusion protein (M‐FP) administered at doses of 1 to 300 microg, given intramuscularly in trial 1 and intraperitoneally in trial 2, with immunizations at weekly intervals (weeks 1 to 3) and repeated in weeks 7 to 9. Cyclophosphamide was given on weeks 1 and 4.
Study: 30095791
Drug: Weekly teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly teriparatide administration starting at 1 week postoperatively
Study: 20590479
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration (WBV) intervention, administered for five 1-minute bouts per session, 3 days per week, for 6 weeks
Study: 18399868
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MTB12 and 38-kDa Ag
Study: 8766893
Drug: 0.18 to
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 to 1.1 g per day of long‐chain polyunsaturated omega‐3 fatty acids (fish oil capsules)
Study: 1672530
Drug: Retinyl palmitate
Normalized name: Retinyl palmitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinyl palmitate (300,000 IU daily for 12 months)
Study: 28108936
Drug: TRAD (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAD (traditional exercise therapy)
Study: 12459350
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (HT) - 4 months of goserelin (3.6 mg every 4 weeks) and flutamide (250 mg t.i.d.) before and during RT
Study: 12459350
Drug: Neoadjuvant hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant hormonal therapy (HT)
Study: 10334230
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal decongestant (oxymetazoline hydrochloride, 0.2 mg per nostril)
Study: 10334230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of decongestant and ENDS
Study: 7503003
Drug: combined felodipine/simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined felodipine/simvastatin therapy
Study: 2021284
Drug: 60 mg/day
Normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/day of Nifedipine
Study: 2021284
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Diltiazem and Nifedipine
Study: 24445291
Drug: Combined higher-dose
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined higher-dose groups (10,000 and 40,000 IU/d)
Study: 20017599
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of azacitidine and cytarabine